The Efficacy of Lymph Node Embolization Using N-Butyl Cyanoacrylate Compared to Ethanol Sclerotherapy in the Management of Symptomatic Lymphorrhea after Pelvic Surgery

Purpose

To compare the efficacy of lymph node (LN) embolization using N-butyl cyanoacrylate versus ethanol sclerotherapy in the management of symptomatic postoperative pelvic lymphorrhea.

Dental arcade arteriovenous fistulas: From diagnosis to treatment with emphasis on the role of endovascular or percutaneous treatment: Single centre experience

ObjectiveDental arcade arteriovenous fistula (DA-AVF) are rare. The purpose of this study was to understand the angioarchitecture of these lesions, changing strategies of endovascular treatment and to analyse the best therapeutic option which will allow normal skeletal development especially in children.Materials and methodsRetrospective study of all the patients of DA-AVF managed at our centre over the last 16 years. Detailed analysis of the clinical features, the imaging findings, endovascular treatment and angiographic outcomes was done.ResultsTotal of six patients were treated. 5 were in the mandible and one in the maxilla. Transarterial glue embolization was done in 3 patients and direct puncture of the intraosseous venous pouch in 2. Transarterial Onyx was used in 2 patients through dual lumen balloon catheter. Overall cure was achieved in 5 out of 6 patients (83%).ConclusionHigh index of suspicion is required to diagnose it on panoramic radiographs. CT/MR/CTA can lead to early diagnosis. Transarterial Onyx embolization using dual lumen balloon catheter is a promising technique & allows excellent penetration of Onyx into the intraosseous venous pouch.     

经皮-肺途径NBCA胶铸型栓塞治疗癌性空洞的临床应用

目的：探讨合并癌性空洞的肺癌患者NBCA胶铸形栓塞的临床价值。方法：根据是否合并空洞内感染,采用经皮-肺途径直接穿刺或空洞内置管引流后NBCA胶铸形栓塞。结果：技术成功率100％,无严重并发症发生,临床症状改善。结论：经皮-肺途径NBCA胶铸形栓塞对合并癌性空洞的肺癌患者是一种有价值的治疗手段,为肺癌的后续治疗创造了很好的治疗条件。     

以动静脉瘘为主的脑动静脉畸形的栓塞治疗

目的探讨以动静脉瘘为主的高血流量脑动静脉畸形(AVM)的血管内栓塞治疗方法.方法将Spinnaker-1.5F微导管送至AVM近动静脉瘘口处,超选择造影测量动静脉微循环时间,先用液态弹簧圈2～3枚经微导管作初步填塞以减慢血流,再根据不同微循环时间配制不同浓度NBCA胶(17%～33%)栓塞AVM.结果采用液态弹簧圈和NBCA胶联合栓塞13例以动静脉瘘为主的AVM,完全栓塞3例,90%栓塞5例,60%栓塞3例,40%栓塞2例,无一例出现并发症.结论采用液态弹簧圈联合NBCA胶能安全、有效地治疗以动静脉瘘为主的脑动静脉畸形.     

Transcatheter Arterial Embolization of Gastrointestinal Bleeding with N-Butyl Cyanoacrylate: A Systematic Review and Meta-Analysis of Safety and Efficacy

Purpose

To evaluate the safety and efficacy of transcatheter arterial embolization with N-butyl cyanoacrylate (NBCA) for the treatment of gastrointestinal (GI) bleeding via a meta-analysis of published studies.

用国产胶体栓塞剂经血管内治疗脑动静脉畸形

报告了经血管内采用微导管超选择导入技术，并应用国产氰基丙烯酸异丁酯（Ｉｓｏｂｕｔｙ１２－ｃｙａｎｏａｃｒｙｌａｔｅ，ＩＢＣＡ）和α－氰基丙烯酸正丁酯（Ｎ－ｂｕｔｙｌｃｙａｎｏａｃｒｙｌａｔｅ，ＮＢＣＡ）栓塞治疗４４例脑动静脉畸形，获较满意效果。文中就栓塞材料的选择、ＩＢＣＡ和ＮＢＣＡ之间的特点比较及应用方法，栓塞术中并发症的预防与处理等进行了讨论。本组资料表明，国产ＩＢＣＡ和ＮＢＣＡ具有与国外产品性能相似的弥散好、易控制、聚合速度快等优点。     

NBCA胶栓塞治疗脑动静脉畸形

目的 评估用a-氰基丙烯酸正丁酯(NBCA)胶栓塞脑动静脉畸形的安全有效性。 方法 回顾性分析NBCA胶栓塞的脑动静脉畸形55例,70次栓塞101根供应动脉。 结果 55例脑动静脉畸形栓塞后,畸形血管团完全消失或栓塞大于90％为16例(29.1％),栓塞70％～90％为23例(41.8％),栓塞50％～69％为9例(16.4％),栓塞<50％为7例(12.7％)。无死亡病例,4例术后出现轻度或严重的神经功能缺损。 结论 NBCA胶栓塞脑动静脉畸形较为安全有效。     

Intranodal Glue Embolization for the Management of Postsurgical Groin Lymphocele and Lymphorrhea

This report describes intranodal lymphatic embolization for treatment of groin lymphatic leaks following surgery or percutaneous vascular interventions. In 10 consecutive patients with groin lymphatic leak between 2015 and 2017, lymphangiography with embolization was performed by intranodal injection with dilute N-butyl cyanoacrylate (NBCA). Mean volume of dilute NBCA (1:3 with ethiodized oil) injected was 1 mL. Clinical success rate was 80%. Median time to resolution was 7 days. Intranodal lymphatic embolization for treatment of groin lymphatic leaks is a safe and effective treatment alternative to surgery resulting in a rapid time to resolution.     

N-Butyl-2-cyanoacrylate-based injectable and in situ-forming implants for efficient intratumoral chemotherapy

The local delivery of chemotherapeutic drugs to tumor sites is an effective approach for achieving therapeutic drug concentrations in solid tumors. Injectable implants with the ability to form in situ represent one of the most promising technologies for intratumoral chemotherapy. However, many issues must be resolved before these implants can be applied in clinical practice. Herein, we report a novel injectable in situ-forming implant system composed of n-butyl-2-cyanoacrylate (NBCA) and ethyl oleate, and the sol–gel phase transition is activated by anions in body fluids or blood. This newly developed injectable NBCA ethyl oleate implant (INEI) is biodegradable, biocompatible, and non-toxic. INEI solidifies in several seconds after exposure to body fluids or blood, and the implant’s in vivo degradation time can be controlled. In addition, the pore sizes formed by the polymerization of NBCA can be decreased by increasing the NBCA concentration in the implants. Therefore, the drug retention/release time can be adjusted from a few weeks to several months by changing the concentration of NBCA in the implant formulation. Anti-tumor experiments in animal models showed that the average growth inhibition rate of xenografted human breast cancer cells by the paclitaxel-loaded INEI (40% NBCA) was 80%, and they also indicated that tumors in some of the mice were completely eliminated by just a single dosage injection. For the epirubicin-loaded INEI (50% NBCA), the average growth inhibition rate of xenografted human liver cancer cells was 58%. Thus, the chemotherapeutic drug-loaded INEIs exhibited excellent therapeutic efficacy for local chemotherapy.